Difference between revisions of "Colnot DR, et al. Cancer Immunol. Immunother. (2003) cited as Ref 554 in DOI: 10.1038/s41392-020-0110-5 (Q9817)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 52, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Safety biodistribution pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck, #quickstatemen...) |
||
Property / title | |||
+ | Safety biodistribution pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck (English) | ||
Property / title: Safety biodistribution pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck (English) / rank | |||
+ | Normal rank |
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language | Label | Description | Also known as |
---|---|---|---|
English |
Colnot DR, et al. Cancer Immunol. Immunother. (2003) cited as Ref 554 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Colnot DR
0 references
2003
0 references
Cancer Immunol. Immunother.
0 references
52
0 references
Safety biodistribution pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck (English)
0 references